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Abstract
Dysregulation of VEGF-A bioavailability has been implicated in the development of lung injury/fibrosis, exemplified by
Idiopathic Pulmonary Fibrosis (IPF). VEGF-A is a target of the hypoxic response via its translational regulation by HIF-1α.
The role of hypoxia and hyperoxia in the development and progression of IPF has not been explored. In normal lung
(NF) and IPF-derived fibroblasts (FF) VEGF-Axxxa protein expression was upregulated by hypoxia, mediated through
activation of VEGF-Axxxa gene transcription. VEGF-A receptors and co-receptors were differentially expressed by hypoxia
and hyperoxia. Our data supports a potential role for hypoxia, hyperoxia and VEGF-Axxxa isoforms as drivers of
fibrogenesis.
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Introduction
Oxygen homeostasis is considered important for the
maintenance of normal lung structure and function [1].
Vascular Endothelial Growth Factor–A (VEGF-A) is tran-
scriptionally regulated by oxygen tension variations, via
Hypoxia Inducible Factor-1 α (HIF-1α) [2]. The VEGF-A
gene is differentially spliced to produce several functioning
isoforms, the subscript number denoting the number of
amino acids in the protein [3]. Proximal splicing in exon 8
produces the conventional ‘angiogenic’ family of isoforms
(VEGF-Axxxa) whilst distal splice site selection produces a
second ‘inhibitory’ family (VEGF-Axxxb) [4, 5]. Of these
two families, VEGF-A165a and VEGF-A165b are the most
widely studied isoforms. In the context of Idiopathic
Pulmonary Fibrosis (IPF), we recently proposed that co-
ordinated expression of the differentially spliced, VEGF-
Axxxa and VEGF-Axxxb isoforms, is important in disease
pathogenesis; alveolar epithelial type II (ATII) cell-derived
VEGF-Axxxa acting as a driver of the fibrotic process, with
protective or anti-fibrotic properties of VEGF-Axxxb [6].
Dense areas of lung fibrosis have been shown to be
hypoxic [7] and high flow oxygen is used therapeutically
in these conditions but the role of hypoxia and hyper-
oxia in the development and progression of IPF is un-
known. We investigated the effect of hypoxia and
hyperoxia on VEGF receptor, co-receptor and VEGF-A
isoform expression in fibroblasts explanted from histo-
logically normal lung (normal fibroblasts, NF) compared
to those from IPF tissue (fibrotic fibroblasts, FF).
Methods
Methodology and statistical analyses are available in
Additional file 1. Additional file 2: Figure S1 details the
primer sequences used to perform quantitative Reverse
Transcriptase Polymerase Chain Reactions (qRTPCR).
Results
Cobalt Chloride induced hypoxic-like growth conditions
in NF and FF cultures, evidenced by HIF-1α expression,
which was absent in normoxic conditions. Interestingly,
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hypoxia induced significantly less HIF-1α expression in
FF than NF (See Additional file 3: Figure S2a).
We examined the effect of hypoxia and hyperoxia on
fibroblast synthetic function. Hypoxia stimulated NF and
FF fibronectin mRNA to the same extent, whilst hyper-
oxia significantly up-regulated fibronectin mRNA in FF
only. In contrast, there was no significant effect of either
hypoxia or hyperoxia on fibroblast pro-collagen-1α (See
Additional file 3: Figure S2b).
We then explored the effect of hypoxia and hyperoxia
on VEGF-A isoform expression. PanVEGF-A and VEGF-
Axxxa mRNA levels were significantly up-regulated in
response to hypoxia in NF and FF, although the FF re-
sponse to hypoxia was significantly less than NF (Fig. 1a).
Quantification of NF and FF panVEGF-A protein cor-
roborated these findings (Fig. 1b). In contrast, hyperoxia
up-regulated panVEGF-A and VEGF-Axxxa mRNA levels
in FF but had no significant effect on NF or FF VEGF-A
protein expression. Similarly, NF and FF VEGF-Axxxb
mRNA (data not shown) and VEGF-A165b protein (Fig. 1b)
were not significantly altered in response to hypoxia or
hyperoxia. Collectively, these data support selective up-
regulation of VEGF-Axxxa proteins in response to hypoxia,
mediated in part through increased transcription.
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Fig. 1 a Vascular endothelial growth factor-A (VEGF-A) mRNA levels in Normal (NF) and Fibrotic (FF) fibroblast total RNA lysates in response to
24 h exposure to hypoxia and hyperoxia. Using quantitative reverse transcriptase polymerase chain reactions (qRT-PCR) of total RNA cell lysates,
panVEGF-A mRNA levels significantly increased in response to hypoxia in NF (****p < 0.0001) and FF (***p < 0.001). The response of FF to hypoxia
was significantly attenuated compared to the NF response (****p < 0.0001). FF panVEGF-A mRNA levels also significantly increased in response to
hyperoxia (p < 0.01), (NF and FF n = 6). Changes in VEGF-Axxxa mRNA levels reflected those seen for panVEGF-A with increased mRNA levels in
response to hypoxia in total RNA lysates of NF (****p< 0.0001) and FF (p< 0.01), an attenuated response of FF to hypoxia compared to NF (***p< 0.001)
and increased FF VEGF-Axxxa mRNA levels in response to hyperoxia (*p< 0.05), (NF and FF n= 6). In contrast, VEGF-Axxxb mRNA levels did not change in
response to hypoxia or hyperoxia (NF and FF n= 6) (data not shown). Data are presented as mean fold change in expression (2^△△CT) with SEM, data
analysis performed on △△CT values. Statistical analysis: analysis of variance with post hoc Holm-Sidak multiple comparisons analysis used throughout.
b VEGF-A isoform protein expression in Normal (NF) and Fibrotic (FF) fibroblast cell lysates in response to 24 h exposure to hypoxia and hyperoxia. By ELISA,
panVEGF-A protein expression in NF and FF cell lysates were significantly up-regulated in response to hypoxia (****p< 0.0001). The response of FF to
hypoxia was significantly attenuated compared to the NF response (****p< 0.0001). Hyperoxia had no significant effect on panVEGF-A protein expression in
NF and FF (NF n= 7, FF n= 7). Using a specific VEGF-A165b ELISA, there was no significant effect of either hypoxia and hyperoxia on VEGF-A165b expression
in both NF and FF (NF and FF n= 6). Data presented as means with SEM, ANOVA with Holm’s Sidak multiple comparisons statistical analysis
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Expression of VEGF-A receptors and co-receptors was
then examined (See Additional file 4: Figure S3). VEGFR1
mRNA expression was significantly up-regulated in NF and
FF in response to hypoxia, although variance in the FF re-
sponse was evident (See Additional file 4: Figure S3a). In
contrast, VEGFR1 protein expression was only signifi-
cantly upregulated in response to hypoxia in NF, although
a similar pattern was observed in FF in response to
hypoxia (See Additional file 4: Figure S3b). Hyperoxia had
no statistically significant effect on VEGFR1 expression in
NF or FF.
VEGFR2 expression was absent in normoxic NF and
FF by western blotting, with levels below the detection
limit (30 pg/ml) of a specific VEGFR2 ELISA (data not
shown), as previously described [6]. VEGFR2 expression
was not stimulated by hypoxia or hyperoxia.
By contrast, hypoxia significantly down-regulated of
NP1 mRNA and protein expression in NF but had no
significant effect on FF. Hyperoxia up-regulated NP1
mRNA and protein expression in FF, but had no signifi-
cant effect on NF (See Additional file 3: Figure S2c).
Both NF and FF NP2 mRNA levels were up-regulated in
response to hypoxia but changes did not translate to the
protein level (See Additional file 4: Figure S3a and c). Fi-
nally, hyperoxia had no significant effect NF and FF NP2
co-receptor expression.
Discussion
Conflicting roles for VEGF-A as both a contributory [6–
8] and protective [9–11] factor in the development of
IPF have been reported. We recently described a para-
digm in which the co-ordinated expression of differen-
tially spliced VEGF-Axxxa and VEGF-Axxxb isoforms is
important for lung fibrogenesis [6], offering a potential
explanation for these apparently conflicting reports. In
this pre-clinical study of murine pulmonary fibrosis,
specific deletion of all VEGF-A isoforms from ATII cells,
over-expression of VEGF-A165b in ATII cells and intra-
peritoneal delivery of VEGF-A165b, all resulted in signifi-
cant amelioration of the fibrotic response. Together
these results indicated that it is the VEGF-Axxxa family
that is profibrotic and the VEGF-Axxxb that is inhibitory/
regulatory. Hypoxia and hyperoxia have been implicated
in the development of IPF [12] and acute lung injury
[13] respectively, but the hypoxia/hyperoxia-VEGF-A
axis has not been examined previously in primary nor-
mal or IPF derived lung fibroblasts.
A hypoxic environment exists in IPF as demonstrated
by HIF-1α expression in IPF but not in normal lung
tissue [12]. Upregulation of VEGF-A in response to hyp-
oxia has been reported in a variety of tissues and cell
types [2]. In this study of NF and FF, hypoxia stimulated
the expression of panVEGF-A but not VEGF-A165b pro-
teins, inferring that specific upregulation of the VEGF-
Axxxa isoforms occured and raises the possibility of pref-
erential VEGF-A gene splicing towards VEGF-Axxxa
isoform production during hypoxia. Since HIF1α levels
were increased in the hypoxic culture conditions, and
VEGF-A is known to be transcriptionally regulated by
HIF-1α, the increased VEGF-Axxxa mRNA observed may
have occurred in part due to HIF-1α activation of
VEGF-Axxxa gene transcription. In IPF, the progressive
nature of the condition results in new areas of tissue
fibrosis developing, which theoretically could provide
ongoing local production of HIF1α to drive this process.
We suggest that further work is required to explore
the contribution of other known regulatory mecha-
nisms of VEGF during hypoxia, such as the post-
transcriptional stabilization of VEGF mRNA through
the formation of a hypoxia-inducible protein complex
at the 3’-UTR of the VEGF gene [14] and the rele-
vance of the functional internal ribosome entry site
which enables efficient cap-independent initiation of
translation during hypoxia [15]. Furthermore, TGF-β
is a potent pro-fibrotic cytokine that has been shown
to co-operate synergistically with hypoxia in stimulat-
ing VEGF gene expression in several cell lines [16]. It
would be interesting therefore to also investigate the
differential production of VEGF-A splice isoforms in
response to TGF-β stimulation.
The response to hypoxia was significantly attenuated
in FF compared to NF, which may reflect a reduction in
HIF-1α-mediated activation of VEGF-A gene transcrip-
tion and implies that the FF were less responsive to hyp-
oxia. In vitro, hypoxia stimulated fibronectin mRNA
levels in NF and FF. In the context of our previous work
[6] and others [12], it provides additional support for
both hypoxia and VEGF-Axxxa isoforms as drivers of
fibrogenesis. We suggest that the observed blunted re-
sponse of FF may be due to exposure to chronic hypoxia
in the context of IPF. This may allow the FF responses
to be overwhelmed by those from more ‘normal areas’ in
this heterogeneous disease. Future work looking specific-
ally at the fibroblastic foci may help clarify this.
We observed differential expression of VEGF receptors
and co-receptors in response to hypoxia. VEGFR1 pro-
tein expression was significantly upregulated in response
to hypoxia in NF. A similar response to hypoxia was ob-
served for FF but this was not statistically significant and
may be explained by substantial variability observed in
the response of individual FF populations. Hypoxic
upregulation of VEGFR1 is a consistent finding in studies
of various cells, which may relate to a hypoxia-inducible
enhancer element within the VEGFR1 gene promoter re-
gion [17]. Whilst this increased VEGFR1 expression may
simply reflect a negative feedback loop for VEGF-A signal-
ing, a role for VEGFR1 in macrophage migration and acti-
vation in fibrosis has been proposed [18].
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NP1 NF expression was downregulated in response to
hypoxia. Existing studies report contradictory findings of
both NP1 upregulation and downregulation in response
to hypoxia depending on the cell type studied [19, 20].
Specific alveolar epithelial cell (AT) NP1 deletion has
been shown to augment the apoptosis of ATI and ATII
cells after exposure to oxidative stressors and have a role
in maintenance of normal alveolar structure [21].
Current paradigms suggest that alveolar epithelial injury
is the initiating factor in IPF [22]. It is possible therefore
that the NP1 down-regulation in response to hypoxia
may influence cell survival and contribute to the fibro-
genic process.
Prolonged breathing of high concentrations of oxygen
is associated with the development of acute lung injury
[13]. The finding that FF panVEGF-A, VEGF-Axxxa and
fibronectin mRNA are all increased in response to
hyperoxia is interesting and suggests further work is re-
quired to investigate the possible pro-fibrotic effects of
hyperoxia in IPF and the role of NP1 as a regulator of
this process. This has important clinical relevance in IPF,
as high flow oxygen is often used therapeutically during
acute exacerbations.
We accept the study is of relatively small numbers of
individual fibroblast populations but is comparable to
several other studies in this field and reflects difficulties
in obtaining tissue samples from these patients. The
authors also acknowledge that HIF-1α may also be se-
creted by the alveolar epithelium. In vitro co-cultures of
IPF-derived alveolar epithelium and fibroblasts would be
desirable to further study the interaction of these cells in
response to hypoxia and hyperoxia but there are several
recognized practical limitations to this [23].
Conclusion
This data reinforces our hypothesis that co-ordinated ex-
pression of VEGF-A isoforms/receptors are important in
the development of pulmonary fibrosis, with support for
hypoxia, hyperoxia and VEGF-Axxxa isoforms as drivers
of fibrogenesis.
Additional files
Additional file 1: Methodology and statistical analyses. (DOCX 23 kb)
Additional file 2: Primer sequences used for quantitative reverse
transcriptase polymerase chain reaction (qRT-PCR). VEGFR1: Vascular
endothelial growth factor receptor 1, VEGFR2: Vascular endothelial
growth factor receptor 2, Neuropilin 1 and 2: NP1 and NP2, For: Forward,
REV: Reverse. (JPEG 90 kb)
Additional file 3: Figure S2. a) Expression of HIF-1α in normal (NF) and
fibrotic (FF) fibroblast cultures following exposure to hypoxic-like growth
conditions with Cobalt Chloride. Representative western blot of NF and
FF cultures treated with (HO) or without (N) Cobalt Chloride (CoCl2) for
24 h (above) with densitometric analysis (below). A specific band was
detected for HIF-1α in cells exposed to CoCl2, that was absent in normoxic
fibroblast cultures (*p < 0.05). Hypoxic-like growth conditions increased
HIF-1α expression to a greater extent in NF compared to FF (*p < 0.05),
unpaired t-test, n = 4 performed, n = 1 shown. Tubulin was used as the
loading control. L: Protein Ladder, N: Normoxia, HO: Hypoxia. b) Quantitative
RT-PCR of Fibronectin and Procollagen-1α mRNA in NF and FF total RNA
lysates following exposure to hypoxia and hyperoxia. Fibronectin mRNA levels
were significantly increased in total RNA lysates of NF and FF fibroblasts
exposed to 24 h of hypoxia (NF *p< 0.05, FF **p< 0.01) and in FF exposed to
24 h of hyperoxia (*p< 0.05) when compared to normoxia using qRT-PCR. In
contrast, hypoxia and hyperoxia had no significant effect on procollagen-1α
mRNA levels. Data are presented as mean fold change in expression (2-△△CT)
with SEM, data analysis performed on △△CT values (NF and FF n= 6). Statistical
analysis: analysis of variance with post hoc Holm-Sidak multiple comparisons
analysis used throughout. (JPEG 53 kb)
Additional file 4: Figure S3. Expression of VEGF-A receptor and co-
receptor mRNA and proteins in response to hypoxia and hyperoxia in
normal (NF) and fibrotic (FF) fibroblasts. a) Quantitative RT-PCR of
VEGFR1, neuropilin (NP) 1, and NP2 mRNA expression in total RNA cell
lysates in NF and FF. VEGFR1 (***p < 0.001) and NP2 (*p < 0.05) mRNA
levels were significantly up-regulated in NF in response to exposure to
hypoxia, whilst NF NP1 mRNA levels were significantly downregulated
(*p < 0.05). Similarly, FF VEGFR1 (*p < 0.05) and NP2 (****p < 0.0001) mRNA
levels were significantly upregulated in response to hypoxia, but NP1
mRNA levels were unaffected. Hyperoxia had no significant effect on
VEGFR1 or NP2 mRNA levels in neither NF or FF, whilst hyperoxia
significantly upregulated (*p < 0.05) FF NP1 mRNA levels. Data are
presented as mean fold change in expression (2-△△CT) with SEM, data
analysis performed on △△CT values (NF and FF n = 6). b) The effect of
hypoxia and hyperoxia on VEGFR1 protein expression in NF and FF as
measured by western blotting (above) and densitometric analysis
(below). VEGFR1 protein expression was significantly upregulated
(***p < 0.001) in response to hypoxia in NF but not in FF. Hyperoxia
had no statistically significant effect on VEGFR1 expression in NF or
FF. c) Hypoxia resulted in the significant down-regulation of NP1
protein expression in NF cell lysates (*p < 0.05), but had no significant
effect on FF. Hyperoxia up-regulated NP1 protein expression in FF
(p* < 0.05), but had no significant effect on NF. d) Hypoxia and
hyperoxia had no significant effect in the expression of NP2 protein.
Data presented as means with SEM (n = 4, n = 2 shown in each
western blot image). Normal: Normal fibroblasts, Fibrotic: Fibrotic
fibroblasts, N: Normoxia, HO: Hypoxia, HE: Hyperoxia. Tubulin: loading
control. Analysis of variance with post hoc Dunnett’s multiple
comparisons analysis used throughout. (JPEG 114 kb)
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